[1] 中华医学会血液学分会浆细胞疾病学组,中国医师协会多发性骨 髓瘤专业委员会 . 中国髓外浆细胞瘤诊断与治疗专家共识(2024 年版) [J]. 中华血液学杂志,2024,45(1):8-17.
[2] Rosiñol L, Beksac M, Zamagni E, et al. Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations[J]. Br J Haematol, 2021, 194(3): 496-507.
[3] 黄蓓晖,李娟,刘俊茹, et al. 多发性骨髓瘤并发髓外浸润的临床分析 [J]. 临床血液学杂志, 2011, 24(2): 151-154,157.
[4] Montefusco V, Gay F, Spada S, et al. Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs[J]. Haematologica, 2020, 105(1): 193-200.
[5] Liu N, WANG L, Liu R, et al. Efficacy and Safety Analysis of Carfilzomib-Containing Regimen in the Treatment of Multiple Myeloma:a Multicenter Real-World Study[J]. Blood, 2023, 142(Supplement 1): 6632-6632. [6] Byun JM, Min CK, Kim K, et al. Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease[J]. J Hematol Oncol, 2022, 15(1): 150.
[7] 刘梦涵,田颖,张月辰,等 . 以米托蒽醌脂质体为基础方案治疗 伴髓外浸润多发性骨髓瘤的疗效和安全性 [J]. 现代中西医结合杂志, 2025,34(7):951-954.
[8] 关海涛,李甜甜,范则杨,等 . CT 引导下经皮冷热交替复合式 冷冻消融治疗肝脏恶性肿瘤近期效果及其安全性 [J]. 中国介入影像 与治疗学,2023,20(4):198-201.